8:00 am Digital Networking Room Opens

8:25 am Chair’s Opening Remarks

• Satu Juhila Project Leader / Early Clinical Development Oncology, Orion Pharma

Developing Innovative Combination Strategies to Unlock Novel Applications of Hippo- Targeted Drugs

8:30 am Per Aspera Ad Astra: The Potential of Hippo Pathway inhibition as a Mono- & Combination Therapy Concept

• Federico Mauri Principal Scientist, Boehringer Ingelheim

9:00 am Panel Discussion: Advancing Hippo Pathway Combination Strategies: Exploring Current & Future Cross-Pathway Opportunities

• Chenglong Li Professor, University of Florida
• Wanjin Hong Chief Business Development Officer, Biomedical Research Council (BMRC) at A*STAR
• Srinivas Vinod Saladi Assistant Professor, University of Toledo, College of Medicine and Life Sciences
• Satu Juhila Project Leader / Early Clinical Development Oncology, Orion Pharma

9:45 am Morning Break & Virtual Networking

Tackling Resistance Mechanisms Driven by the Hippo Pathway to Effectively Develop Combination Strategies Against MAPK & EGFR Cancers

10:30 am Determining New Roles of the Hippo Pathway in Driving Cancer Formation, Progression & Adaptive Resistance to Inform Combination Strategies

• Srinivas Vinod Saladi Assistant Professor, University of Toledo, College of Medicine and Life Sciences

11:00 am Exploring Resistance Mechanisms in MAPK-Addicted Cancers: YAP Upregulation, Immune Suppression, & Innovative Combination Strategies for Hippo Pathway Targeted Drugs

• Kari Kurppa Principal Investigator & Academy Research Fellow, University of Turku

11:30 am Drug Persistence Versus Drug Resistance to KRAS G12C Inhibitors & implications for YAP/TAZ Targeted Drugs

• Alessia Mira Senior Postdoc, Molecular Biotechnology Center, University of Torino

12:00 pm Lunch Break & Virtual Networking